[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630060":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":23,"responsibleParty":39,"collaborators":10,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":43,"sex":49,"minAge":50,"maxAge":10,"enrollmentInfo":51,"targetDuration":10,"studyType":54,"phases":10,"briefSummary":55,"conditions":56,"keywords":10,"overallStatus":58,"whyStopped":10,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},{"fullName":5,"class":6},"BIWAKO","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"FFPE samples",null,"Samples obtained from patients with multiple myeloma disease and confirmed 4;14 translocation. Tissu samples should be obtained (nos aspirate)",[13],{"name":14,"affiliation":15,"role":16},"Heba RASHED","MEDARKCRO","PRINCIPAL_INVESTIGATOR",[18],{"name":19,"role":20,"phone":21,"phoneExt":10,"email":22},"Marie BREVET, Pr ; MD. PhD.","CONTACT","+33628010948","m.brevet@biwako.fr",[24],{"facility":5,"status":10,"city":25,"state":10,"zip":26,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"Lyon","69006","France","FR",{"type":30,"coordinates":31},"Point",[32,33],4.84789,45.74906,{"lat":33,"lon":32},[36],{"name":37,"role":20,"phone":38,"phoneExt":10,"email":22},"Marie BREVET","0628010948",{"type":40,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100630060","multiple-myeloma-t4-14-ffpe-samples-100630060",false,"NCT07482761","Multiple Myeloma t(4 ;14) FFPE Samples","Discovery And Validation Of New Biomarkers In The Context Of Multiple Myeloma With t(4-14) and Relapse","MM-t4-14-FFPE","Inclusion Criteria:\n\n* Adult patients with histologically confirmed myeloma with a t(4;14) translocation\n* Availability of a representative FFPE block from a surgical specimen.\n* Diagnosis established within the past 10 years.\n* Availability of associated clinical and follow-up data.\n\nExclusion Criteria:\n\n* Bone lesions samples\n* Insufficient or non-representative FFPE material.\n* Missing key diagnostic or clinical data.","ALL","18 Years",{"count":52,"type":53},20,"ESTIMATED","OBSERVATIONAL","This observational study aims to evaluate the feasibility of assembling a retrospective cohort of formalin-fixed paraffin-embedded (FFPE) tissue samples from patients with 4;14 translocated multiple myeloma, together with their associated clinical and pathological data. The study will determine whether these archived samples are suitable for exploratory biomarker assessment.\n\nNo intervention is performed. All FFPE samples and clinical data originate exclusively from routine diagnostic procedures and will be analyzed retrospectively for research purposes.",[57],"Multiple Myeloma and Malignant Plasma Cell Neoplasms","NOT_YET_RECRUITING","2026-03-14",{"date":61,"type":62},"2026-03-19","ACTUAL",{"date":64,"type":53},"2026-07-05",{"date":66,"type":53},"2027-06-01",{"name":5,"class":6},1]